Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Osteoprotegerin

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101718

Synonyms

Historical Background

It has been estimated that around 10% of total bone mass is renewed per year leading to a full replacement of the bone tissue every 10 years. This biological mechanism called “bone remodeling” plays a central role in calcium and phosphorus homeostasis and is the result of a balance between osteoclast and osteoblast activities. Indeed, osteoclasts originating from hematopoietic stem cells resorb bone (Rousselle and Heymann 2002); and in contrast, osteoblasts, which come from mesenchymal stem cells, are specialized in the formation of new mineralized extracellular matrix (Dechaseaux et al. 2009). For many years, a central regulation based on hormone network including parathyroid hormone (PTH) or calcitonin has been considered as the key system modulating the bone remodeling in addition to the local homeostasis driven by interleukin-6 or prostaglandin E2 (PGE2). Thus, osteoclast and osteoblast activities are able to control each other, and mesenchymal stem cells and osteoblasts have been well known to modulate osteoclast differentiation and bone degradation. The late 1990s have been marked by the identification of the key master proteins Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL), RANK, and Osteoprotegerin (OPG), which control the intimate communications between osteoblasts and osteoclasts. OPG was originally discovered in 1997 by two research teams independently. Boyle’s group generated transgenic mice overexpressing various TNF receptor cDNAs and one of them exhibited a huge osteoporotic phenotype associated with a defect of osteoclastogenesis (Simonet et al. 1997). The corresponding protein encoded by this cDNA was named osteoprotegerin from the latin “osteo” (bone) and “protegere” (to protect). On the same time, Tsuda’s group identified a repressor of osteoclast differentiation, which they named Osteoclast Inhibitory Factor (OCIF) (Tsuda et al. 1997; Yasuda et al. 1998a). OCIF and OPG were in fact the same protein belonging to the TNF receptor superfamily and its international name according to the TNF nomenclature is TNFRSF11B. One year later, the first ligand of OPG was identified and called OPG Ligand (OPGL) and Osteoclast Differentiation Factor (ODF) by both groups (Yasuda et al. 1998b; Lacey et al. 1998). OPG ligand was similar to a soluble protein previously named TNF-related activation-induced cytokine (TRANCE) and which was expressed after activation of T-cell receptor. RANKL/TRANCE was a member of the TNF superfamily, which bound to RANK, a transmembrane trimeric receptor (Anderson et al. 1997). Since this time, RANKL/RANK/OPG constitute the master molecular triad controlling bone resorption and this discovery has led to opening up entirely new areas in bone field (Baud’huin et al. 2013), especially the development of therapies (e.g., anti-RANKL antibody Denosumab) (Bekker et al. 2004).

Molecular Characteristics of OPG, Its Pattern of Expression, and Its Multiple Ligands

The gene encoding OPG is located on chromosomes 8 and 15 in human and mouse, respectively (Table 1). Northern blot analysis using a full-length cDNA probe produced a major transcript of 2.4. Two additional transcripts of 4.2 and 6.5 kb were detected and represented alternatively spliced forms containing all or a portion of the second intron that encodes for a soluble molecule. The corresponding protein is composed by 401 amino acids for a molecular weight of around 55 kDa. OPG is a soluble protein, and the most active form is a dimeric structure. OPG presents a large spectrum of expression and is considered as an ubiquitous protein (Table 1). OPG is more particularly expressed in bone marrow stromal cells, endothelial cells, and epithelial intestinal cells. Its expression is regulated by numerous biological and chemical compounds involved in the bone, vascular, and immune biological systems.
Osteoprotegerin, Table 1

OPG characteristics and its patterns of expression

Chromosomal location

Human 8q24

Mouse Ch15

Size

Molecular weight

Stoichiometry

401 as

55 kDa

Soluble monomer and dimer

Homology

Mouse/human 66%

Main pattern of cellular expression

Bone marrow stromal cells, immune and hematopoietic cells (dendritic cells, follicular dendritic cells, lymphoid cells, monocytes, B and T lymphocytes, megakaryocytes), endothelial cells, fibroblasts, osteoblast, epithelial intestinal cells

Main pattern of tissue expression

Smooth muscle cells, bone, bone marrow, brain, calvaria, heart, intestines, kidney, liver, lung, mammary gland, placenta, prostate, skin, spinal cord, spleen, stomach, thyroid, cartilage

Inhibitors

PGE2, Glucocorticoid, PTH, PTHrP, IGF1, Indomethacin, cyclosporin A, tacrolimus, dexamethasone, ionomycin, calcium, indian hedgehog

Activators

17P-estradiol, MP-2, GH, IL-1b, IL13, IL-18, IL-6, LIF, OSM, PDGF, TGFP, IFNy, RA.NKL, TNFa, FGF2, MIPla, cAMP, forskolin, inorganic phosphate, activitin A, epinephrine, leptin, triiodothyronine, _ ethanol, nitric oxide, bisphophonate

OPG has a signal peptide (amino acids 1–21) and is composed by seven complementary domains (Fig. 1a). The protein contains four cystein-rich domains at the N-terminal region (amino acids 22–185) that corresponds to the RANKL-binding domain and could be also associated with the binding domain to TRAIL (TNF-Related Apoptosis Inducing Ligand). Amino acids 195–401 form the dimerization domain and contain four death domain homologous (DDH) regions and a heparin-binding domain. In N-terminal position, Cys400 is the residue responsible to the dimerization process. The physiological function of the DDH remains unknown; however, these domains are potentially functional as demonstrated by the overexpression in cells of a chimeric protein composed by OPG and the Fas transmembrane domain that results in cell apoptosis (Yamaguchi et al. 1998). The heparin-binding allows the OPG binding to numerous proteoglycans and glycosaminoglycans and controls its half-life and bioavailability (Théoleyre et al. 2006). OPG do not exhibit apparent transmembane domain and consequently is exclusively secreted under a soluble form.
Osteoprotegerin, Fig. 1

In agreement with its molecular characteristics, OPG possesses several different ligands. (a) OPG is characterized by a peptide signal and by seven structural domains linked to its ability to bind to various ligands. The cysteine-binding domains are used for its binding to RANKL, and the c-terminal domains including death domain–homologous regions and heparin domains with the Cys400 are required for its dimerization; (b) Dimeric OPG binds to trimeric RANKL, to TRAIL vWF, FVIII/vWF, proteoglycans, and glycosaminoglycans (GAGs); (c) Table summarizing an equilibrium dissociation constant of OPG to its ligands; (d) In bone cells, RANKL released by osteoblasts binds to RANK expressed by osteoclast precursors and induces osteoclast differentiation and bone resorption. OPG secreted by osteoblasts acts as a decoy receptor for RANKL, interrupts the binding of RANKL to RANK, and then inhibits the bone resorption

Based on these molecular features, OPG cannot only bind to RANKL but can interact with numerous ligands (Fig. 1b). OPG can interact with TRAIL with an equilibrium dissociation constant (KD) around 24 × 10 −9M (Emery et al. 1998) and is physically colocalized with von Willebrand factor into the Weibel-Palade bodies located in endothelial cells (Baud’huin et al. 2013) (Fig. 1c). The interaction between vWF and Factor VIII (FVII)/vWF do not affect the coagulation parameters. Glycosaminoglycans bind to OPG, and dermatan sulfate and chondroitin sulfate showed the highest binding affinity (Fig. 1c). The functional aspects of these interactions will be described in the paragraphs below.

OPG Is a Powerful Inhibitor of Osteoclastogenesis and Bone Resorption

The role of OPG has been established initially by the differential bone phenotype exhibited by transgenic and knockout mice. Indeed, OPG knockout mice were osteoporotic with a marked decrease of their bone mineral density and with a high incidence of spontaneous fractures and spine deformities (Bucay et al. 1998). This phenotype was totally reversed by the administration of recombinant OPG. In contrast, OPG transgenic mice showed an osteopetrosis associated with a strong decrease of osteoclastogenesis and an impairment of thymocyte development (Simonet et al. 1997). As expected, RANKL knockout mice were osteopetrotic with a defect in tooth eruption explained by a total absence of osteoclasts due to the osteoblast inability to support osteoclastogenesis. RANKL transgenic mice were osteoporotic with an exacerbated activation of osteoclast differentiation. In bone tissue, OPG is mainly secreted by osteoblasts and mesenchymal stromal cells, which produced membrane-bound and soluble RANKL (Fig. 1d). RANK is expressed by osteoclast precursors and mature osteoclasts, and the binding of RANKL to the extracellular RANK domain leads to the expression of specific genes involved in osteoclast differentiation, bone resorption, and osteoclast survival. OPG prevents the binding of RANKL to RANK and consequently inhibits osteoclast differentiation and bone resorption. OPG acts as a decoy receptor for RANKL.

OPG Presents a Large Panel of Biological Functions More Specifically in the Control of Immune and Vascular Systems

Consistent with its ubiquitous expression, OPG exerts its functions beyond the bone tissue (Fig. 2). Indeed, OPG showed biological activities in immune and vascular systems (Baud’huin et al. 2007). OPG is a CD40-regulated gene in B cells and dendritic cells. Chino et al. (2009) revealed that OPG regulated the DC survival and DC-dependent inflammatory responses. Dendritic cells from homozygous OPG-deficient mice potentiate the mixed leukocyte reaction despite CD86, MHCII, and antigen presentation levels, which are similar to heterozygous mice (Yun et al. 2001). In OPG-deficient mice, the increased proliferation of pro-B cells in response to IL-7 is associated with a deficit in antibody response, which is explained by an alteration in the isotype switching of IgG. Thus, Yun et al. (2001) observed an accumulation of type 1 transitional B cells in spleen. In contrast, OPG transgenic mice did not show any alterations of immune development or organization. OPG exerts a chemotactic activity in human circulating monocytes through its interaction to syndecan-1 through its heparin-binding domain (Mosheimer et al. 2005).
Osteoprotegerin, Fig. 2

Multiple functions of OPG. In addition to its first biological activity as an inhibitor of osteoclast differentiation and bone resorption, OPG contributes to the control of the immune system by regulating the proliferation of pro-B cells and their maturation, the chemoattraction of monocytes/macrophages, and the biology of dendritic cells. Consequently, OPG and its ligand became the key regulators of osteoimmunology. More recently, it has been shown that endothelial cell survival and proliferation as well as the formation of microvessels are stimulated by OPG. Related to these diverse functions, OPG has been linked with various diseases

In vascular system, OPG promotes endothelial cell survival through αvβ3 and NF-κB pathways (Pritzker et al. 2004; Baud’huin et al. 2007). OPG stimulates the proliferation of endothelial colony-forming cells in vitro and the formation of microvessel in vivo (Benslimane-Ahmin et al. 2011). Furthermore, OPG bound to the vWF in endothelial cells is secreted in response to inflammatory signals. More recently, Kondegowda et al. (2015) demonstrated that OPG enhanced mouse and human β-cell proliferation, and OPG activation resulted in an increase of β-cell mass in healthy and diabetic mice. In this system, OPG abrogates the inhibitory effects of RANKL on β-cell proliferation. This last observation underlines the potential interest of OPG in diabetes treatment.

OPG and Its Dysregulation Are Related to Various Disorders

According to its inhibitory effect on bone resorption, OPG has been strongly related to the bone loss associated diseases (e.g., postmenopausal osteoporosis, bone loss in Crohn’s disease, bone destruction in rheumatoid arthritis) (Théoleyre et al. 2004). Osteoporosis is a multifactorial disease including genetic susceptibility and environmental factors. In this context, polymorphisms of OPG correlating with the risk of osteoporosis were identified (Zofkova et al. 2015). In rheumatoid arthritis, OPG acts as expected as a bone protector but has no effect on inflammation.

Growing evidence indicates that OPG has a strong impact directly and indirectly in oncology (Théoleyre et al. 2004; Lamoureux et al. 2010). Indeed, OPG binding to TRAIL leads to the neutralization of TRAIL apoptotic activity, a natural inducer of tumor cell apoptosis. In this case, OPG can act as a survival factor in several cancer types and could have a deleterious impact (Emery et al. 1998). Myeloma cells express CD138 (syndecan-1), which can bind OPG, and then controls its bioavailability by increasing its internalization and degradation. This mechanism is associated with an increase of local RANKL concentration and a high osteolysis level, which establishes a favorable niche for tumor growth. OPG expression by tumor endothelial cells also correlates with a proangiogenic phenotype and with clinical data in human tumors. Then, OPG is able to block the vicious cycle established between cancer cells and their bone microenvironment, especially osteoclasts and blood vessels (Lamoureux et al. 2010). Jones et al. (2006) demonstrated the role of RANKL in the control of the metastatic process. Indeed, numerous cancer cells express RANK and are sensitive to RANKL. RANKL triggers the migration of RANK expressing cancer cells in vitro and in vivo, and OPG abolishes RANKL activities and strongly reduces the tumor burden in bone exclusively. More recently, Yoldi et al. (2016) showed that the inhibition of RANK signaling markedly decreases the cancer stem cell pool in breast cancer as well as the tumor and metastasis initiation and enhances sensitivity to chemotherapy.

The role of OPG in vascular diseases has been provided by the vascular phenotype of OPG-deficient mice, which exhibited medial calcification of the aorta and renal arteries (Bucay et al. 1998). OPG is expressed more frequently in atheromatous carotid plaques than in femoral arteries and correlates with the macrophage infiltration (Davaine et al. 2014, 2016). Diabetic patients with uncontrolled glycemia showed increased levels of OPG associated with atherosclerosis and increased morbidity/mortality linked to vascular diseases. Interestingly, OPG administration in mice prevents vascular calcifications induced by warfarin or high vitamin D doses (Baud’huin et al. 2013). This observation suggested that OPG and its molecular partners could play a role in association between osteoporosis and vascular calcifications. Numerous epidemiological studies report the association between circulating OPG and incident of cardiovascular diseases. However, it remains unclear if the impact of OPG on cardiovascular system results from an active pathway (e.g., signaling through proteoglycans) or from a passive mechanism (e.g., TRAIL blockade or inhibition of RANKL signaling) (Bernardi et al. 2016).

Summary

In 1997, the identification of OPG, a powerful inhibitor of osteoclast differentiation and bone resorption, was the first signal of a scientific revolution in the field of bone biology. With RANKL, its main ligand OPG/RANKL is the master proteins at the origin of a new topic named osteoimmunology. Indeed, OPG/RANKL is functionally involved in bone remodeling and in immune system by controlling dendritic cells survival and B-lymphocyte maturation. However, OPG activities were not restricted to bone and immunity, and OPG delivered progressively its secrets and multiple functional facets. OPG showed its ability to bind to numerous ligands such as TRAIL, proteoglycans, glycoaminoglycans, vWF, and FVIII/vWF complex and plays consequently functional activities in diverse biological systems such as endothelial cells or β-cell proliferation. OPG is clearly related to (i) osteoporosis with identified polymorphisms; (ii) cancer development by modulating tumor cell survival and migration and by regulating the tumor niches (e.g., bone, immune, and vascular niches); (iii) cardiovascular diseases by active (e.g., OPG binding to syndecan-1) or passive mechanisms (e.g., inhibition of TRAIL activities or RANKL signaling). Even if OPG by itself remains difficult to manipulate as therapeutic tool due to its multiple ligands, OPG has led to the development of RANKL inhibitors used in clinical trials, and OPG remains a fascinating therapeutic target/agent in numerous benign and malignant diseases.

References

  1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–9. doi: 10.1038/36593.PubMedCrossRefGoogle Scholar
  2. Baud’huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, et al. Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev. 2013;24:401–9. doi: 10.1016/j.cytogfr.2013.06.001.PubMedCrossRefGoogle Scholar
  3. Baud’huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci. 2007;64:2334–50. doi: 10.1007/s00018-007-7104-0.PubMedCrossRefGoogle Scholar
  4. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059–66. doi: 10.1359/JBMR.040305.PubMedCrossRefGoogle Scholar
  5. Benslimane-Ahmim Z, Heymann D, Dizier B, Lokajczyk A, Brion R, Laurendeau I, et al. Osteoprotegerin: a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost. 2011;9:834–43. doi: 10.1111/j.1538-7836.2011.04207.x.PubMedCrossRefGoogle Scholar
  6. Bernardi S, Bossi F, Toffoli B, Fabris B. Roles and clinical applications of opg and trail as biomarkers in cardiovascular disease. Biomed Res Int. 2016;2016:1752854. doi: 10.1155/2016/1752854.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Caparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–8.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Chino T, Draves KE, Clark EA. Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J Leukoc Biol. 2009;86:933–40. doi: 10.1189/jlb.0708419.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Davaine JM, Quillard T, Brion R, Lapérine O, Guyomarch B, Merlini T, et al. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability. PLoS One. 2014;9:e107642. doi: 10.1371/journal.pone.0107642.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Davaine JM, Quillard T, Chatelais M, Guilbaud F, Brion R, Guyomarch B, et al. Bone like arterial calcification in femoral atherosclerotic lesions: prevalence and role of osteoprotegerin and pericytes. Eur J Vasc Endovasc Surg. 2016;51:259–67. doi: 10.1016/j.ejvs.2015.10.004.PubMedCrossRefGoogle Scholar
  11. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363–7.PubMedCrossRefGoogle Scholar
  12. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692–6. doi: 10.1038/nature04524.PubMedCrossRefGoogle Scholar
  13. Kondegowda NG, Fenutria R, Pollack IR, Orthofer M, Garcia-Ocaña A, Penninger JM, et al. Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-κB ligand pathway. Cell Metab. 2015;22:77–85. doi: 10.1016/j.cmet.2015.05.021.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.PubMedCrossRefGoogle Scholar
  15. Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochim Biophys Acta. 2010;1805:17–24. doi: 10.1016/j.bbcan.2009.08.004.PubMedGoogle Scholar
  16. Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, Wiedermann CJ. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab. 2005;90:2964–71.PubMedCrossRefGoogle Scholar
  17. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell. 2004;15:2834–41. doi: 10.1091/mbc.E04-01-0059.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Rousselle AV, Heymann D. Osteoclastic acidification pathways during bone resorption. Bone. 2002;30:533–40.PubMedCrossRefGoogle Scholar
  19. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–19.PubMedCrossRefGoogle Scholar
  20. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457–75.PubMedCrossRefGoogle Scholar
  21. Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun. 2006;347:460–7. doi: 10.1016/j.bbrc.2006.06.120.PubMedCrossRefGoogle Scholar
  22. Tsuda E, Goto M, Michizuki S, Yano K, Kobayashi F, Morinaga T, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997;234:137–42.PubMedCrossRefGoogle Scholar
  23. Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem. 1998;273:5117–23.PubMedCrossRefGoogle Scholar
  24. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998a;139:1329–37. doi: 10.1210/endo.139.3.5837.PubMedCrossRefGoogle Scholar
  25. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998b;95:3597–602.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Yoldi G, Pellegrini P, Trinidad EM, Cordero A, Gomez-Miragaya J, Serra-Musach J, et al. RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation. Cancer Res. 2016;76(19):5857–69. doi: 10.1158/0008-5472.CAN-15-2745.PubMedCrossRefGoogle Scholar
  27. Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, et al. Osteoprotegerin: a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol. 2001;166:1482–91.PubMedCrossRefGoogle Scholar
  28. Zofkova I, Nemcikova P, Kuklik M. Polymorphisms associated with low bone mass and high risk of atraumatic fracture. Physiol Res. 2015;64:621–31.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.INSERM, UMR957, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses PrimitivesUniversity of NantesNantesFrance
  2. 2.Department of Oncology and MetabolismInserm, European Associated Laboratory “Sarcoma Research Unit”, The Medical School, University of SheffieldSheffieldUK